207 related articles for article (PubMed ID: 22035748)
1. Monitoring of minimal residual disease in acute myeloid leukemia: methods and best applications.
Jorgensen JL; Chen SS
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S49-53. PubMed ID: 22035748
[TBL] [Abstract][Full Text] [Related]
2. Combining flow cytometry and
Guolo F; Minetto P; Clavio M; Miglino M; Galaverna F; Raiola AM; Di Grazia C; Colombo N; Pozzi S; Ibatici A; Bagnasco S; Guardo D; Kunkl A; Ballerini F; Ghiggi C; Lemoli RM; Gobbi M; Bacigalupo A
Haematologica; 2017 Sep; 102(9):e348-e351. PubMed ID: 28495917
[No Abstract] [Full Text] [Related]
3. Relevance of leukemic stem cells in acute myeloid leukemia: heterogeneity and influence on disease monitoring, prognosis and treatment design.
Wouters R; Cucchi D; Kaspers GJ; Schuurhuis GJ; Cloos J
Expert Rev Hematol; 2014 Dec; 7(6):791-805. PubMed ID: 25242511
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of minimal residual disease detected by multidimensional flow cytometry: serial monitoring after allogeneic stem cell transplantation for acute leukemia.
Miyazaki T; Fujita H; Fujimaki K; Hosoyama T; Watanabe R; Tachibana T; Fujita A; Matsumoto K; Tanaka M; Koharazawa H; Taguchi J; Tomita N; Sakai R; Fujisawa S; Kanamori H; Ishigatsubo Y
Leuk Res; 2012 Aug; 36(8):998-1003. PubMed ID: 22551655
[TBL] [Abstract][Full Text] [Related]
5. [Advances in minimal residual disease detection with flow cytometry in childhood acute myeloid leukemia].
Feng JH; Xu XJ; Tang YM
Zhonghua Er Ke Za Zhi; 2013 Mar; 51(3):231-4. PubMed ID: 23751588
[No Abstract] [Full Text] [Related]
6. Minimal Residual Disease in Acute Myeloid Leukemia.
Sung PJ; Luger SM
Curr Treat Options Oncol; 2017 Jan; 18(1):1. PubMed ID: 28110381
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease markers before and after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
Dominietto A
Curr Opin Hematol; 2011 Nov; 18(6):381-7. PubMed ID: 21986564
[TBL] [Abstract][Full Text] [Related]
8. Should evaluation for minimal residual disease be routine in acute myeloid leukemia?
Coustan-Smith E; Campana D
Curr Opin Hematol; 2013 Mar; 20(2):86-92. PubMed ID: 23380603
[TBL] [Abstract][Full Text] [Related]
9. Monitoring of minimal residual disease in acute myeloid leukemia.
Kern W; Schoch C; Haferlach T; Schnittger S
Crit Rev Oncol Hematol; 2005 Nov; 56(2):283-309. PubMed ID: 16213150
[TBL] [Abstract][Full Text] [Related]
10. Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia.
Marani C; Clavio M; Grasso R; Colombo N; Guolo F; Kunkl A; Ballerini F; Giannoni L; Ghiggi C; Fugazza G; Ravetti JL; Gobbi M; Miglino M
Leuk Res; 2013 Dec; 37(12):1606-11. PubMed ID: 23891447
[TBL] [Abstract][Full Text] [Related]
11. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia.
Al-Mawali A; Gillis D; Lewis I
Am J Clin Pathol; 2009 Jan; 131(1):16-26. PubMed ID: 19095561
[TBL] [Abstract][Full Text] [Related]
12. Readying the minimal residual disease concept in acute myeloid leukaemia for prime time - the American way.
Hokland P; Cotter F
Br J Haematol; 2013 Aug; 162(4):429-30. PubMed ID: 23772825
[No Abstract] [Full Text] [Related]
13. Molecular characterization of acute myeloid leukemia and its impact on treatment.
Frankfurt O; Licht JD; Tallman MS
Curr Opin Oncol; 2007 Nov; 19(6):635-49. PubMed ID: 17906465
[TBL] [Abstract][Full Text] [Related]
14. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.
Terwijn M; van Putten WL; Kelder A; van der Velden VH; Brooimans RA; Pabst T; Maertens J; Boeckx N; de Greef GE; Valk PJ; Preijers FW; Huijgens PC; Dräger AM; Schanz U; Jongen-Lavrecic M; Biemond BJ; Passweg JR; van Gelder M; Wijermans P; Graux C; Bargetzi M; Legdeur MC; Kuball J; de Weerdt O; Chalandon Y; Hess U; Verdonck LF; Gratama JW; Oussoren YJ; Scholten WJ; Slomp J; Snel AN; Vekemans MC; Löwenberg B; Ossenkoppele GJ; Schuurhuis GJ
J Clin Oncol; 2013 Nov; 31(31):3889-97. PubMed ID: 24062400
[TBL] [Abstract][Full Text] [Related]
15. A refined approach to detect and measure minimal residual disease in childhood acute myeloid leukemia by flow cytometry.
Capolunghi F; Capponi C; De Stefani B; Luciani M; Locatelli F; Muraca M; Carsetti R
Am J Hematol; 2014 Mar; 89(3):343-4. PubMed ID: 24265183
[No Abstract] [Full Text] [Related]
16. Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets.
Rossi G; Minervini MM; Carella AM; de Waure C; di Nardo F; Melillo L; D'Arena G; Zini G; Cascavilla N
Leuk Res; 2012 Apr; 36(4):401-6. PubMed ID: 22196957
[TBL] [Abstract][Full Text] [Related]
17. Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms.
Ossenkoppele GJ; van de Loosdrecht AA; Schuurhuis GJ
Br J Haematol; 2011 May; 153(4):421-36. PubMed ID: 21385170
[TBL] [Abstract][Full Text] [Related]
18. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.
Rizzari C; Cazzaniga G; Coliva T; De Angelis C; Conter V
Expert Rev Anticancer Ther; 2011 Sep; 11(9):1391-401. PubMed ID: 21929313
[TBL] [Abstract][Full Text] [Related]
19. Development of minimal residual disease-directed therapy in acute myeloid leukemia.
Freeman SD; Jovanovic JV; Grimwade D
Semin Oncol; 2008 Aug; 35(4):388-400. PubMed ID: 18692689
[TBL] [Abstract][Full Text] [Related]
20. Monitoring of minimal residual disease in acute leukemia by multiparametric flow cytometry.
Kusenda J; Fajtova M; Kovarikova A
Neoplasma; 2014; 61(2):119-27. PubMed ID: 24299307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]